Charles River Laboratories International, Inc. (NYSE:CRL) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) have been assigned a consensus rating of “Moderate Buy” from the sixteen ratings firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and twelve have given a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $211.00.

Several research firms recently commented on CRL. Barclays boosted their price objective on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Robert W. Baird set a $213.00 price objective on shares of Charles River Laboratories International in a research note on Friday, May 8th. CLSA raised shares of Charles River Laboratories International from a “hold” rating to an “outperform” rating and boosted their price objective for the stock from $167.00 to $219.00 in a research note on Friday, May 29th. Weiss Ratings lowered shares of Charles River Laboratories International from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 16th. Finally, Mizuho set a $192.00 price objective on shares of Charles River Laboratories International in a research note on Friday, May 8th.

Charles River Laboratories International Trading Down 0.0%

Shares of CRL opened at $215.68 on Monday. The firm’s 50-day moving average price is $176.98 and its 200-day moving average price is $183.33. The firm has a market capitalization of $10.39 billion, a price-to-earnings ratio of -57.36, a PEG ratio of 2.46 and a beta of 1.46. The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90. Charles River Laboratories International has a 1-year low of $144.26 and a 1-year high of $228.88.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.96 by $0.10. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The firm had revenue of $995.83 million for the quarter, compared to analyst estimates of $977.46 million. During the same quarter in the previous year, the firm posted $2.34 EPS. The company’s revenue for the quarter was up 1.2% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Sell-side analysts anticipate that Charles River Laboratories International will post 11.05 EPS for the current year.

Institutional Investors Weigh In On Charles River Laboratories International

Several hedge funds have recently bought and sold shares of CRL. Cardinal Capital Management raised its holdings in Charles River Laboratories International by 0.6% in the fourth quarter. Cardinal Capital Management now owns 10,928 shares of the medical research company’s stock worth $2,180,000 after buying an additional 62 shares during the last quarter. Asset Management One Co. Ltd. raised its holdings in Charles River Laboratories International by 4.0% in the fourth quarter. Asset Management One Co. Ltd. now owns 1,847 shares of the medical research company’s stock worth $375,000 after buying an additional 71 shares during the last quarter. Glenmede Trust Co. NA raised its holdings in Charles River Laboratories International by 2.8% in the first quarter. Glenmede Trust Co. NA now owns 2,706 shares of the medical research company’s stock worth $467,000 after buying an additional 73 shares during the last quarter. Mercer Global Advisors Inc. ADV raised its holdings in Charles River Laboratories International by 1.3% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 6,316 shares of the medical research company’s stock worth $1,260,000 after buying an additional 80 shares during the last quarter. Finally, Advisory Services Network LLC raised its holdings in Charles River Laboratories International by 2.6% in the third quarter. Advisory Services Network LLC now owns 3,226 shares of the medical research company’s stock worth $505,000 after buying an additional 83 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.